345 related articles for article (PubMed ID: 23463481)
21. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
Grépin R; Pagès G
J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
[TBL] [Abstract][Full Text] [Related]
22. [Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].
Clément-Duchêne C; Godbert B; Martinet Y
Rev Mal Respir; 2012 Feb; 29(2):161-77. PubMed ID: 22405111
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
24. Current insights on the biology and clinical aspects of VEGF regulation.
Birk DM; Barbato J; Mureebe L; Chaer RA
Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
26. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer.
Yang F; Jin C; Jiang YJ; Li J; Di Y; Fu DL
Expert Rev Anticancer Ther; 2011 Apr; 11(4):541-9. PubMed ID: 21504321
[TBL] [Abstract][Full Text] [Related]
27. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
28. VEGF-targeted therapy: mechanisms of anti-tumour activity.
Ellis LM; Hicklin DJ
Nat Rev Cancer; 2008 Aug; 8(8):579-91. PubMed ID: 18596824
[TBL] [Abstract][Full Text] [Related]
29. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
Sharma PS; Sharma R; Tyagi T
Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
[TBL] [Abstract][Full Text] [Related]
30. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
33. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.
Yang AD; Bauer TW; Camp ER; Somcio R; Liu W; Fan F; Ellis LM
Cancer; 2005 Apr; 103(8):1561-70. PubMed ID: 15754332
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
35. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
36. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
37. Beyond bevacizumab: antiangiogenic agents.
Rogosin S; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
[TBL] [Abstract][Full Text] [Related]
38. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
Klamerus JF; Brahmer JR
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
[TBL] [Abstract][Full Text] [Related]
40. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]